Scholar Rock Holding Corporation (SRRK)

NASDAQ: SRRK · IEX Real-Time Price · USD
5.88
+0.55 (10.32%)
At close: Jul 5, 2022 4:00 PM
6.07
+0.19 (3.23%)
Pre-market: Jul 6, 2022 8:25 AM EDT

Company Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.

The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases.

Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation
Scholar Rock Holding Logo
Country United States
Founded 2012
IPO Date May 24, 2018
Industry Biotechnology
Sector Health Care
Employees 145
CEO Nagesh Mahanthappa

Contact Details

Address:
620 Memorial Dr Fl 2
Cambridge, Massachusetts 02139-4815
United States
Phone 857 259 3860
Website scholarrock.com

Stock Details

Ticker Symbol SRRK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001727196
CUSIP Number 80706P103
ISIN Number US80706P1030
Employer ID 82-3750435
SIC Code 2836

Key Executives

Name Position
Dr. Nagesh K. Mahanthappa MBA, Ph.D. Interim Chief Executive Officer, President and Director
Edward H. Myles M.B.A., MBA Chief Financial Officer, Chief Operating Officer and Treasurer
Dr. Gregory John Carven Ph.D. Chief Scientific Officer
Catherine Hu Vice President of Investor Relations and Corporate Communications
Junlin Ho J.D. General Counsel and Corporate Secretary
Caryn Parlavecchio Chief Human Resources Officer
Lisa Amaya Price Senior Vice President of Human Resources
Dr. George G. Nomikos M.D., Ph.D. Senior Vice President of Medical and Clinical Sciences and Head of Muscle Therapeutic Area
Erin Moore Senior Vice President of Finance
Ryan Iarrobino Senior Vice President of Clinical Development and Operations

Latest SEC Filings

Date Type Title
Jun 27, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
Jun 24, 2022 3 Initial statement of beneficial ownership of securities
Jun 21, 2022 8-K Current report
Jun 21, 2022 424B5 Prospectus [Rule 424(b)(5)]
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities